Niya Bowers used two examples of data collection sets to illustrate what the study results have shown on temperature control.
Due to the limited information for non-cold chain products in certain shipping lanes, the Bill and Melinda Gates Foundation is running a study on temperature-sensitive drug distribution in LMICs (low- and middle-income countries).
Speaking at the virtualPDA/FDA2020 PDA/FDA Joint Regulatory Conference,Niya Bowers, the senior program officer for the Foundation, presented the study on the global health supply chain which focused on the typical excursion range for global health room temperature products in zone 4b and global health (GH) shipping lanes.
The foundation has partnered with Chemonics–a management systems supplier–who designed the study and gathers and reports data through the use of sensors placed on the shipments–monitoring changes in temperature, humidity, pressure, vibration, and shocks. Data is gathered from the manufacturer’s warehouse all the way to the healthcare post in the destination country. This includes data for transportation by boat, plane, and truck, as well as in central and regional warehouses, pharmacies, and healthcare clinics. Data is also being collected for twelve-month periods in those locations to cover seasonal changes.
See it Live at PACK EXPO Connects Nov. 9-13: See Heat Seal’s live demo of our ALL NEW automatic, all electric combination shrink system, by Heat Seal/Ampak. Preview the Showroom Here.
Bowers used two examples of data collection sets to illustrate what the study results have shown:
The first was a two-week long air transportation from Belgium to Mozambique. The sensors indicated that the temperature ranged from 5°C to 45°C.
The second was the transportation of a product from Thailand to Zimbabwe–first by sea, then by air. Its recorded temperature range was from 10°C to 55°C.
Sensors showed the biggest changes in trucks with temperatures of up to 60°C and 100% humidity.
The Foundation’s focused efforts on developing a better global, low-cost manufacturers network and mitigating technical and quality risks for new product approvals have resulted in collaborations with 12 partners to develop a portfolio of GH products as well as connections with nearly 45 manufacturers across India, China, Bangladesh, and Africa. These connections and collaborations have led to TB treatment approval by the FDA and EMA, anti-malaria ACTs and contraceptives, and COVID-19 emergency response in LMICs.
“There is no free lunch and we must be invested in quality in order to achieve impact,” says Bowers.
The study is ongoing; the data will be analyzed by an AI platform which will then be consolidated, disseminated, and published by Chemonics.
The Foundation will work with the uninformed but cannot work with the intentionally fraudulent.
Uninformed or Intentionally Fraudulent
There are few options for producing low-cost quality drugs, and one of them is to work with low-cost manufacturers. This would leverage the labor costs in the region. Hence, the Foundation has started an extensive network with low-cost manufacturers in areas such as India and China, where new drugs are being produced for those areas.
Bowers says that there are two types of companies: the uninformed and the intentionally fraudulent.
She explains that the Foundation will work with the uninformed but cannot work with the other. For this reason, low cost manufacturers must undergo in-depth evaluation and extensive upfront assessments before they will be accepted as partners, after which, the collaboration must focus on all three areas of quality, technical capability, and manufacturing capacity.
“We will bring quality subject matter experts to onsite due-diligence visits” says Bowers. “After the decision is made, and the grant is given, we provide ongoing quality experts support and other subject matter experts to improve the grantee's quality systems and other technical capabilities throughout the grant lifetime.”
PACK EXPO Connects Trend Chat
Rarely does an entirely new industry emerge in packaging and processing, but the legalization of cannabis for medical and adult-use did just that. Sit in as Healthcare Packaging Editor Keren Sookne and PMMI Media Group’s VP of Content Jim Chrzan chat with Greg Flickinger of Green Thumb International (GTI) about the industry’s response to cannabis packaging. PACK EXPO Connects Trend Chat Monday, November 9 • 2:30 PM - 3:00 PM CT. More info here.
Discover the latest breakthrough packaging technologies shaping the pharmaceutical sector. This report dives into cutting-edge innovations, from smart containers that enhance patient safety to eco-friendly materials poised to transform the industry’s sustainability practices. All from PACK EXPO. Learn how forward-thinking strategies are driving efficiency and redefining what’s possible in pharma packaging.
FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
